Construction of Predictive Models for Cancer-specific Survival of Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Results from a Multicenter Retrospective Study

被引:6
|
作者
Nishiyama, Naotaka [1 ]
Kitamura, Hiroshi [1 ]
Hotta, Hiroshi [2 ]
Takahashi, Atsushi [3 ]
Yanase, Masahiro [4 ]
Itoh, Naoki [5 ]
Tachiki, Hitoshi [6 ]
Miyao, Noriomi [7 ]
Matsukawa, Masanori [8 ]
Kunishima, Yasuharu [9 ]
Taguchi, Keisuke [10 ]
Masumori, Naoya [1 ]
机构
[1] Sapporo Med Univ, Dept Urol, Sch Med, Sapporo, Hokkaido 0608543, Japan
[2] Asahikawa Red Cross Hosp, Dept Urol, Asahikawa, Hokkaido, Japan
[3] Hakodate Goryoukaku Hosp, Dept Urol, Hakodate, Hokkaido, Japan
[4] Sunagawa City Med Ctr, Dept Urol, Sunagawa, Japan
[5] NTT East Japan Sapporo Hosp, Dept Urol, Sapporo, Hokkaido, Japan
[6] Steel Mem Muroran Hosp, Dept Urol, Muroran, Hokkaido, Japan
[7] Muroran City Gen Hosp, Dept Urol, Muroran, Hokkaido, Japan
[8] Takikawa Municipal Hosp, Dept Urol, Takikawa, Hokkaido, Japan
[9] Hokkaido Social Work Assoc Obihiro Hosp, Dept Urol, Obihiro, Hokkaido, Japan
[10] Oji Gen Hosp, Dept Urol, Tomakomai, Japan
关键词
non-muscle-invasive bladder cancer; bacillus Calmette-Guerin; BCG failure classification; UROTHELIAL CARCINOMA; PROGNOSTIC-FACTORS; RISK; MANAGEMENT; FAILURE; TUMORS; PROGRESSION; RECURRENCE; THERAPY; DISEASE;
D O I
10.1093/jjco/hyu119
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aims of this study were to clarify the prognostic factors and to validate the bacillus Calmette-Guerin failure classification advocated by Nieder et al. in patients with non-muscle-invasive bladder cancer who had intravesical recurrence after bacillus Calmette-Guerin therapy. Methods: Data from 402 patients who received intravesical bacillus Calmette-Guerin therapy between January 1990 and November 2011 were collected from 10 institutes. Among these patients, 187 with bacillus Calmette-Guerin failure were analyzed for this study. Results: Twenty-nine patients (15.5%) were diagnosed with progression at the first recurrence after bacillus Calmette-Guerin therapy. Eighteen (62.1%) of them died of bladder cancer. A total of 158 patients were diagnosed with non-muscle-invasive bladder cancer at the first recurrence after bacillus Calmette-Guerin therapy. Of them, 23 (14.6%) underwent radical cystectomy. No patients who underwent radical cystectomy died of bladder cancer during the follow-up. On multivariate analysis of the 135 patients with bladder preservation, the independent prognostic factors for cancer-specific survival were age (>= 70 [P = 0.002]), tumor size (>= 3 cm [P = 0.015]) and the Nieder classification (bacillus Calmette-Guerin refractory [P < 0.001]). In a subgroup analysis, the estimated 5-year cancer-specific survival rates in the groups with no positive, one positive and two to three positive factors were 100, 93.4 and 56.8%, respectively (P < 0.001). Conclusions: Patients with stage progression at the first recurrence after bacillus Calmette-Guerin therapy had poor prognoses. Three prognostic factors for predicting survival were identified and used to categorize patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin into three risk groups based on the number of prognostic factors in each one.
引用
收藏
页码:1101 / 1108
页数:8
相关论文
共 50 条
  • [21] Role of oral pentosan polysulfate in Bacillus Calmette-Guerin therapy in patients with non-muscle-invasive bladder cancer
    Lee, Ho Yeon
    Jung, Seung Il
    Lim, Do Gyeong
    Chung, Ho Seok
    Hwang, Eu Chang
    Kwon, Dong Deuk
    INVESTIGATIVE AND CLINICAL UROLOGY, 2022, 63 (05) : 539 - 545
  • [22] Gender-Specific Differences in Recurrence and Progression following Bacillus Calmette-Guerin Instillation for Non-Muscle-Invasive Bladder Cancer
    Schneidewind, Laila
    Kiss, Bernhard
    Kranz, Jennifer
    Zengerling, Friedemann
    Borkowetz, Angelika
    Graf, Sebastian
    Graser, Annabel
    Uhlig, Annemarie
    UROLOGIA INTERNATIONALIS, 2024,
  • [23] Intravesical bacillus Calmette-Guerin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer
    Ekin, Rahmi Gokhan
    Akarken, Ilker
    Zorlu, Ferruh
    Tarhan, Huseyin
    Kucuk, Ulku
    Yildirim, Zubeyde
    Divrik, Rauf Taner
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (5-6): : E278 - E283
  • [24] Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guerin? Predictors and Nomograms
    Faba, Oscar Rodriguez
    Pisano, Francesca
    Krajewski, Wojciech
    Breda, Alberto
    Palou, Joan
    UROLOGIC CLINICS OF NORTH AMERICA, 2020, 47 (01) : 5 - 13
  • [25] Immune Predictors of Response after Bacillus Calmette-Guerin Treatment in Non-Muscle-Invasive Bladder Cancer
    Rodriguez-Izquierdo, Marta
    Del Canizo, Carmen G.
    Rubio, Carolina
    Reina, Ignacio A.
    Arroyo, Mario Hernandez
    Antolin, Alfredo Rodriguez
    Porto, Marta Duenas
    Guerrero-Ramos, Felix
    CANCERS, 2023, 15 (23)
  • [26] Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Non-muscle-invasive Bladder Cancer
    Rink, Michael
    Xylinas, Evanguelos
    Babjuk, Marko
    Pycha, Armin
    Karakiewicz, Pierre I.
    Novara, Giacomo
    Dahlem, Roland
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2012, 62 (06) : 1204 - 1206
  • [27] Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)
    Abou Chakra, Mohamad
    Duquesne, Igor
    Peyromaure, Michael
    Mott, Sarah L.
    Moussa, Mohamad
    O'Donnell, Michael A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (03) : 315 - 324
  • [28] Treatment Options Available for Bacillus Calmette-Guerin Failure in Non-muscle-invasive Bladder Cancer
    Yates, David R.
    Brausi, Maurizio A.
    Catto, James W. F.
    Dalbagni, Guido
    Roupret, Morgan
    Shariat, Shahrokh F.
    Sylvester, Richard J.
    Witjes, J. Alfred
    Zlotta, Alexandre R.
    Palou-Redorta, Juan
    EUROPEAN UROLOGY, 2012, 62 (06) : 1088 - 1096
  • [29] PROGNOSTIC SIGNIFICANCE OF BACILLUS CALMETTE-GUERIN FAILURE CLASSIFICATION IN NON-MUSCLE-INVASIVE BLADDER CANCER
    Singh, Bhupendra Pal
    Dhakad, Urmila
    BJU INTERNATIONAL, 2012, 110 (06) : E163 - E164
  • [30] Bacillus Calmette-Guerin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
    Tan, Wei Shen
    Grajales, Valentina
    Bree, Kelly
    Li, Roger
    Nogueras-Gonzalez, Graciela M.
    Navai, Neema
    Dinney, Colin
    Kamat, Ashish M.
    BJU INTERNATIONAL, 2023, 132 (04) : 384 - 386